Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study

被引：0
|
作者：
Ciruelos, E. M. [1 ]
Hamilton, E. P. [2 ]
Kim, S-B. [3 ]
Im, Y-H. [4 ,5 ]
Solis, E. Segui [6 ]
Saenz, J. A. Garcia [7 ]
Di Sanzo, A. [8 ]
Lizarbe, M. Dominguez [9 ]
Wasserman, T. [10 ]
Theall, K. P. [11 ]
Ibrahim, N. K. [12 ]
机构：
[1] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Med Dept Hematol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Med Oncol Div, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
[6] Hosp Clin August Pi Sunyer Biomed Res Inst IDIBAP, Dept Med Oncol, Barcelona, Spain
[7] Inst Invest Sanitaria Hosp Clinico San Carlos, Dept Med Oncol, Madrid, Spain
[8] Biostatist & Data Management Dept, Menarini Grp, Florence, Italy
[9] Menarini Grp, Clin Res Dept, Florence, Italy
[10] Global Med Affairs Dept, Menarini Grp, Florence, Italy
[11] Global Product Dev Dept, Menarini Grp, New York, NY USA
[12] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
364P
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)
    Chae, Heejung
    Sim, Sung Hoon
    Kwon, Youngmi
    Lee, Eun-Gyeong
    Han, Jai Hong
    Jung, So-Youn
    Lee, Seeyoun
    Kang, Han-Sung
    Kim, Yeon-Joo
    Kim, Tae Hyun
    Lee, Keun Seok
    CANCERS, 2024, 16 (18)
  • [22] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
    Jhaveri, Komal
    Winer, Eric Paul
    Lim, Elgene
    Fidalgo, Jose AlejandroPerez
    Bellet, Meritxell
    Mayer, Ingrid Alina
    Boni, Valentina
    Patel, Jaymin M.
    Bardia, Aditya
    Garcia, Jose Manuel
    Kabos, Peter
    Gates, Mary
    Chen, Ya-Chi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori Sickels
    Spoerke, Jill
    Gendreau, Steven
    Metcalfe, Ciara
    Liu, Lichuan
    Chang, Ching-Wei
    Monemi, Sharareh
    Gonzalez, Monica
    McCurry, Ursula
    Milan, Sandra
    Humke, Eric William
    Loi, Sherene
    CANCER RESEARCH, 2020, 80 (04)
  • [23] A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, D. A.
    Blakely, L.
    Hemphill, B.
    Joseph, M.
    Liggett, W.
    Daniel, B.
    Castrellon, A.
    Shastry, M.
    Finney, L.
    DeBusk, L.
    Hainsworth, J. D.
    Burris, H. A., III
    CANCER RESEARCH, 2017, 77
  • [24] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [25] Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).
    Moore, Heather M.
    Boni, Valentina
    Bellet, Meritxell
    De Las Heras, Begona Bermejo
    Cortes, Maria Gion
    Oakman, Catherine
    Schmid, Peter
    Trinh, Xuan Bich
    Wheatley, Duncan
    Jhaveri, Komal L.
    Kabos, Peter
    Lim, Elgene
    Velu, Thierry
    Metcalfe, Ciara
    Gates, Mary R.
    Chang, Ching-Wei
    Bond, John
    Goldstein, Leonard D.
    Lauchle, Jennifer O'Hara
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).
    Martin, Miguel
    Lim, Elgene
    Mac Gregor, Mariana Chavez
    Shivhare, Mahesh
    Ross, Graham
    Patre, Monika
    Roncoroni, Laura
    Louka, Maria
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
    Juric, Dejan
    Bedard, Phillippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Oliveira, Mafalda
    Saura, Cristina
    Kalinsky, Kevin M.
    Hamilton, Erika
    Italiano, Antoine
    Krop, Ian E.
    Schmid, Peter
    Turner, Nicholas C.
    Varga, Andrea
    Royer-Joo, Stephanie
    Hutchinson, Katherine E.
    Schutzman, Jennifer L.
    Jhaveri, Komal L.
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
    Martin, Miguel
    Lim, Elgene
    Chavez-MacGregor, Mariana
    Bardia, Aditya
    Wu, Jiong
    Zhang, Qingyuan
    Nowecki, Zbigniew
    Cruz, Felipe Melo
    Safin, Rustem
    Kim, Sung-Bae
    Schem, Christian
    Montero, Alberto J.
    Khan, Sarah
    Bandyopadhyay, Reeti
    Moore, Heather M.
    Shivhare, Mahesh
    Patre, Monika
    Martinalbo, Jorge
    Roncoroni, Laura
    Perez-Moreno, Pablo Diego
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (18) : 2149 - 2160
  • [29] Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
    Vidal, Maria
    Falato, Claudette
    Pascual, Tomas
    Sanchez-Bayona, Rodrigo
    Munoz-Mateu, Montserrat
    Cebrecos, Isaac
    Gonzalez-Farre, Xavier
    Cortadellas, Tomas
    Vila, Mireia Margeli
    Luna, Miguel A.
    Siso, Christian
    Amillano, Kepa
    Galvan, Patricia
    Bergamino, Milana A.
    Ferrero-Cafiero, Juan M.
    Salvador, Fernando
    Espinosa Guerrero, Alejandra
    Pare, Laia
    Sanfeliu, Esther
    Prat, Aleix
    Bellet, Meritxell
    CLINICAL CANCER RESEARCH, 2025, 31 (07) : 1223 - 1232
  • [30] A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial
    Ottenbourgs, Tine
    van Gorp, Toon
    Kridelka, Frederic
    Baert, Thais
    Denys, Hannelore
    Selle, Frederic
    Baas, Inge
    Van Rompuy, Anne-Sophie
    Lambrechts, Diether
    Van Nieuwenhuysen, Els
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 627 - 630
12345